Developed by Baxalta (which was then acquired by Shire), Rixubis was only the second recombinant factor IX (rfIX) therapy approved for hemophilia B, and the first to be indicated for routine prophylaxis treatment in adults upon its 2013 approval. Rixubis is produced in Chinese hamster ovary cells and is purified using viral inactivation and removal steps. No other human- or animal-derived products are used during the manufacturing of Rixubis.
LIST OF FIGURES 8 Figure 26: BAY 94-9027 for hemophilia – SWOT analysis
9 Figure 27: Datamonitor Healthcare’s drug assessment summary of BAY 94-9027 for hemophilia
10 Figure 28: Datamonitor Healthcare’s drug assessment summary of BAY 94-9027 for hemophilia
12 Figure 29: BAY 94-9027 sales for hemophilia across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES 5 Table 1: Rixubis drug profile
7 Table 2: Rixubis pivotal trial data in hemophilia
13 Table 3: Rixubis sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.